EMD Serono lays out MS ther­a­pies' im­mune-sys­tem sup­pres­sion risks in new cam­paign

EMD Serono is lean­ing on drug dif­fer­en­ti­a­tion in a new dig­i­tal and so­cial me­dia cam­paign for Maven­clad, its mul­ti­ple scle­ro­sis treat­ment.

The “B Cells and RMS” cam­paign de­scribes the B cell and po­ten­tial long-term im­mune sys­tem sup­pres­sion that can oc­cur in MS pa­tients tak­ing high-ef­fi­ca­cy ther­a­pies (HET), in­clud­ing mon­o­clon­al an­ti­bod­ies like Roche’s Ocre­vus and Bio­gen’s Tysabri, and S1P mod­u­la­tors like No­var­tis’ Mayzent. Maven­clad is al­so an HET, al­though it tem­porar­i­ly sup­press­es the im­mune sys­tem.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER